These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36896828)

  • 1. Predictors of recurrence after paclitaxel drug-coated balloon use for treating femoropopliteal in-stent restenosis.
    Taha AG; Saleh MI; Ali H; Gamal WM
    Vascular; 2024 Aug; 32(4):834-841. PubMed ID: 36896828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Coated Balloon for the Treatment of Femoropopliteal Tosaka Class III In-stent Restenosis Lesions.
    Zhang B; Niu G; Yan Z; Zou Y; Tong X; Yang M
    Front Surg; 2020; 7():616414. PubMed ID: 33521048
    [No Abstract]   [Full Text] [Related]  

  • 3. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and Comparative Analysis of the Initial Results of Standard Balloon Angioplasty Versus Drug-Coated Balloons Alone Versus in Association With Laser-Excimer Atherectomy in the Treatment of Femoropopliteal Artery In-Stent Restenosis (INTACT).
    Ducasse E; Sapoval M; Brunet J; Commeau P; Goueffic Y; Sabatier J; Steinmetz E; Lermusiaux P; Rosset E; Caradu C
    J Endovasc Ther; 2024 Apr; ():15266028241248333. PubMed ID: 38659343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M; Keirse K; Scheinert D; Spak L; Jaff MR; Schmahl R; Li P; Zeller T;
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2113-2123. PubMed ID: 29050631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis).
    Dippel EJ; Makam P; Kovach R; George JC; Patlola R; Metzger DC; Mena-Hurtado C; Beasley R; Soukas P; Colon-Hernandez PJ; Stark MA; Walker C;
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):92-101. PubMed ID: 25499305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous Mechanical Atherectomy Plus Thrombectomy Using the Rotarex®S Device Followed by a Drug-Coated Balloon for the Treatment of Femoropopliteal Artery In-stent Restenosis: A Prospective Single-Center, Single-Arm Efficacy Trial (PERMIT-ISR Trial).
    Liu MY; Li W; Guo X; Zhang Z; Liu B; Yu H; Zhang Z; Chen X; Feng H
    Front Surg; 2021; 8():671849. PubMed ID: 34595204
    [No Abstract]   [Full Text] [Related]  

  • 8. Debulking plus drug-coated balloon angioplasty versus drug-coated balloon angioplasty alone for femoropopliteal Tosaka III in-stent restenosis lesions.
    Li L; Tong Z; Cui S; Guo L
    Wideochir Inne Tech Maloinwazyjne; 2023 Mar; 18(1):166-172. PubMed ID: 37064559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laser Atherectomy Combined With Drug-Coated Balloon Angioplasty Is Associated With Improved 1-Year Outcomes for Treatment of Femoropopliteal In-Stent Restenosis.
    Kokkinidis DG; Hossain P; Jawaid O; Alvandi B; Foley TR; Singh GD; Waldo SW; Laird JR; Armstrong EJ
    J Endovasc Ther; 2018 Feb; 25(1):81-88. PubMed ID: 29219030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Femoropopliteal In-stent Restenosis Repair: Midterm Outcomes After Paclitaxel Eluting Balloon Use (PLAISIR Trial).
    Bague N; Julia P; Sauguet A; Pernès JM; Chatelard P; Garbé JF; Penillon S; Cardon JM; Commeau P; Planché O; Guyomarch B; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2017 Jan; 53(1):106-113. PubMed ID: 27890526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
    Liistro F; Grotti S; Porto I; Angioli P; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1295-302. PubMed ID: 24239203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
    Giannopoulos S; Kokkinidis DG; Jawaid O; Behan S; Hossain P; Alvandi B; Foley TR; Singh GD; Waldo SW; Armstrong EJ
    Cardiovasc Revasc Med; 2020 Jun; 21(6):771-778. PubMed ID: 31761634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry.
    Tepe G; Zeller T; Moscovic M; Corpataux JM; Christensen JK; Keirse K; Nano G; Schroeder H; Binkert CA; Brodmann M
    J Endovasc Ther; 2020 Apr; 27(2):304-315. PubMed ID: 31989855
    [No Abstract]   [Full Text] [Related]  

  • 14. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
    Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
    J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study.
    Liistro F; Angioli P; Porto I; Ricci L; Ducci K; Grotti S; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2014 Feb; 21(1):1-8. PubMed ID: 24502477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jetstream Atherectomy in Treating Femoropopliteal In-Stent Restenosis: Meta-Analysis of the JETSTREAM-ISR and JET-ISR Trials.
    Shammas NW; Jones-Miller S; Shammas GA; Shammas WJ
    J Invasive Cardiol; 2020 Aug; 32(8):289-294. PubMed ID: 32737264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs.
    Kayssi A; Al-Atassi T; Oreopoulos G; Roche-Nagle G; Tan KT; Rajan DK
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011319. PubMed ID: 27490003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.
    Auffret V; Berland J; Barragan P; Waliszewski M; Bonello L; Delarche N; Furber A; Albert F; Carrié D; Eltchaninoff H; Pansieri M; Schneeberger M; Piot C; Marcollet P; Bedossa M
    Int J Cardiol; 2016 Jan; 203():690-6. PubMed ID: 26583844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.